Darpa Buys Into Tiny Computer Chips Firm

A new law allows Pentagon to become venture capitalist to support domestic firms deemed vital to national security SANTA CLARA, CALIF. -- When Jerry E. Crowley threw a lunch last fall for potential investors, he was looking for a few risk-taking venture capitalists to help out his company, Gazelle Microcircuits Inc., a small startup electronics firm here in Silicon Valley. But instead of someone from the private sector, Crowley managed to tap a totally unexpected source of funds: the Departme

Written byFrederic Golden
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


A new law allows Pentagon to become venture capitalist to support domestic firms deemed vital to national security
SANTA CLARA, CALIF. -- When Jerry E. Crowley threw a lunch last fall for potential investors, he was looking for a few risk-taking venture capitalists to help out his company, Gazelle Microcircuits Inc., a small startup electronics firm here in Silicon Valley.

But instead of someone from the private sector, Crowley managed to tap a totally unexpected source of funds: the Department of Defense (DOD). What's more, the money came not in the form of a traditional research-and-development grant but as a direct investment that could, if Crowley's company takes off, actually yield a profit for the Pentagon.

The novel agreement is between Gazelle and the Defense Advanced Research Projects Agency, or DARPA, the Pentagon's R&D arm. It was made possible by an experimental program passed by Congress last year that allows ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies